Exhibit 4.2


 


WARRANT AGREEMENT


 


This Warrant Agreement
made as of [___________], 2016, is between BioLight Life Sciences Ltd., an Israeli company, with offices at Kiryat Atidim Building
3, 5th Floor, Tel Aviv 6158101, Israel (the “Company”), and VStock Transfer, LLC, with offices at
18 Lafayette Place, Woodmere, New York 11598 (the “Warrant Agent”).


 


WHEREAS, the Company
has determined to issue and deliver up to [_________] warrants (the “Warrants”) to investors, each Warrant evidencing
the right of the holder thereof to purchase one ordinary share, NIS 2.5 par value per share (the “Ordinary Shares”),
for $[___] of the Company, subject to adjustment as described herein.


 


WHEREAS, the Company
desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance,
registration, transfer, exchange, redemption and exercise of the Warrants;


 


WHEREAS, the Company
desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the
respective rights, limitation of rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and


 


WHEREAS, all acts and
things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned
by or on behalf of the Warrant Agent, as provided herein, the legally valid and binding obligations of the Company, and to authorize
the execution and delivery of this Warrant Agreement.


 


NOW, THEREFORE, in
consideration of the mutual agreements herein contained, the parties hereto agree as follows:


 


1.       
   Appointment of Warrant Agent. The Company hereby appoints the Warrant
Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to
perform the same in accordance with the terms and conditions set forth in this Agreement.


 


2.      
    Warrants.


 


2.1           Form
of Warrant. Each Warrant shall be (a) issued in registered form only, (b) in substantially the form of Exhibit A attached
hereto, the provisions of which are incorporated herein, (c) signed by, or bear the facsimile or electronic signature of, any two
of the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer of the Company, and (d) signed by the
Warrant Agent. In the event that a person whose facsimile signature has been placed upon any Warrant shall have ceased to serve
in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as
if he or she had not ceased to be such at the date of issuance.


 




     


     


    




 


2.2          Effect
of Countersignature. Unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant shall be invalid
and of no effect and may not be exercised by the holder thereof. Warrant certificates shall be dated the date of countersignature
by the Warrant Agent.


 


2.3          Registration.



 


2.3.1           Warrant
Register. The Warrant Agent shall maintain books (“Warrant Register”), for the registration of the original
issuance and transfers of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the
Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered
to the Warrant Agent by the Company.


 


2.3.2           Registered
Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant shall be registered upon the Warrant Register (“Registered Holder”),
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other
writing on the warrant certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.


 


3.  
        Terms and Exercise of
Warrants.


 


3.1          Exercise
Price. Each Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate and of this Warrant
Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of US$___ per Ordinary Share,
subject to the subsequent adjustments provided in Section 4 hereof. The term “Exercise Price” as used in this
Warrant Agreement refers to the price per share at which Ordinary Shares may be purchased at the time a Warrant is exercised. 


 


3.2          Duration of Warrants. A Warrant may be exercised only during the period
(“Exercise Period”) commencing on the date of issuance. For purposes of this Warrant Agreement, the “Expiration
Date” shall have the meaning set forth in the Warrant Certificate. Each Warrant not exercised on or before the Expiration
Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close
of business on the Expiration Date. 


 


3.3          Exercise
of Warrants.


 


3.3.1           Payment.
Subject to the provisions of the Warrant and this Agreement, a Warrant, when countersigned by the Warrant Agent, may be exercised
by the Registered Holder thereof by (i) submitting a duly executed exercise notice in the form included in Exhibit B, to
the office of the Warrant Agent [____________] which may be done by fax or email delivery, and (ii) by paying to the Company in
full the Exercise Price for each whole Ordinary Share as to which the Warrant is exercised, in lawful money of the United States,
by wire transfer or in good certified check or good bank draft payable to the order of the Company.  In no event shall
the Registered Holder of any Warrant be entitled to “net cash settle” the Warrant. The Registered Holder shall not
be required to deliver the original Warrant being exercised in order to effect an exercise hereunder.  


 




    2 


     


    




 


***Checks should be payable to BioLight
Life Sciences Ltd. Notice of cash exercise should be made by e-mail (not fax) to [__________]. Originals need to be mailed
to BioLight Life Sciences Ltd., Attention: [____________]. Wired funds for exercise should be wired to:


 


[_________________]


 


3.3.2           Issuance
of Ordinary Shares. Assuming the exercise notice has been delivered and funds to pay
in full the Exercise Price are paid, each in accordance with Section 3.3.1, then on or before the third trading day following the
date upon which (1) the Warrant Agent has received an exercise notice for a Warrant and (2) the Company has received the funds
in full, the Company shall cause its transfer agent to (i) provided that the transfer agent is participating in The Depository
Trust Company (“DTC”) Fast Automated Securities Transfer Program, credit such aggregate number of Ordinary Shares
to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC
through its Deposit/Withdrawal at Custodian System, or (ii) if the transfer agent is not participating in the DTC Fast Automated
Securities Transfer Program, issue and deliver to the Holder, or at the Holder’s instruction pursuant to the delivered exercise
notice, the Holder’s agent or designee, in each case pursuant to this clause (ii), sent by reputable overnight courier to
the address specified in the applicable exercise notice, a certificate, registered in the Company’s share register in the
name of the Holder or its designee (as indicated in the applicable exercise notice), for the number of Ordinary Shares to which
the Holder is entitled pursuant to such exercise. 


 


3.3.3           Valid Issuance. All Ordinary Shares issued upon the proper exercise or surrender
of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.


 


3.3.4           Date
of Issuance. Each person or entity in whose name any such certificate for Ordinary Shares is issued shall, for all purposes,
be deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the
Exercise Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and
payment is a date when the share transfer books of the Company are closed, such person shall be deemed to have become the holder
of such shares at the close of business on the next succeeding date on which the share transfer books are open.


 




    3 


     


    

  


3.4           Beneficial
Ownership Limitation on Exercises. The Company shall not affect the exercise of any portion of a Warrant, and the Registered
Holder of such Warrant shall not have the right to exercise any portion of such Warrant, to the extent that after giving effect
to such exercise, the Registered Holder (together with the Registered Holder’s affiliates, and any persons acting as a group
together with the Registered Holder or any Registered Holder’s affiliates) would beneficially own in excess of 4.99% (the
“Maximum Percentage”) of the Ordinary Shares outstanding immediately after giving effect to such exercise, provided, however,
that the foregoing limitation on exercise shall not apply to any Registered Holder who, together with such Registered Holder’s
affiliates, and any persons acting as a group together with such Registered Holder and such Registered Holder’s affiliates,
owns in excess of the Maximum Percentage immediately prior to the closing of the Offering.  For purposes of the foregoing
sentence, the aggregate number of Ordinary Shares beneficially owned by such Registered Holder and its affiliates shall include
the number of Ordinary Shares issuable upon exercise of a Warrant with respect to which the determination of such sentence is being
made, but shall exclude Ordinary Shares which would be issuable upon (i) exercise of the remaining, unexercised portion of such
Warrant beneficially owned by the Registered Holder and its affiliates and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company beneficially owned by the Registered Holder and its affiliates (including, without
limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Registered Holder or any of its affiliates.  Except
as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  To the
extent that the limitation contained in this Section 3.4 applies, the Registered Holder’s submission of an Election to Purchase
shall be deemed to be the Registered Holder’s determination of whether a Warrant is exercisable (in relation to any other
securities owned by the Registered Holder together with any affiliates) and of which portion of a Warrant is exercisable, in each
case subject to the Maximum Percentage, and the Company shall have no obligation to verify or confirm the accuracy of such determination.  In
addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of the Warrants, in determining
the number of outstanding Ordinary Shares, the Registered Holder may rely on the number of outstanding Ordinary Shares as reflected
in the most recent of (1) the Company’s most recent Form 20-F, Form 6-K or other public filing with the Commission, as the
case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or its transfer agent
setting forth the number of Ordinary Shares outstanding.  For any reason at any time, upon the written or oral request
of the Registered Holder, the Company shall within three (3) trading days confirm to the Registered Holder the number of Ordinary
Shares then outstanding.  In any case, the number of outstanding Ordinary Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including any Warrant, by the Registered Holder and its affiliates
since the date as of which such number of outstanding Ordinary Shares was reported.  By written notice to the Company,
the Registered Holder may from time to time increase or decrease the Maximum Percentage to any other percentage of the number of
Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares upon exercise of a Warrant and the
provisions of this Section 3.4 shall continue to apply; provided that (i) any such increase will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to that Registered
Holder.  For purposes of clarity, the Ordinary Shares underlying any Warrant in excess of the Maximum Percentage for
a Registered Holder shall not be deemed to be beneficially owned by that Registered Holder for any purpose including for purposes
of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.  The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 3.4 to the extent necessary to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation.


 




    4 


     


    




 


4.   
       Adjustments.


 


4.1          Share
Dividends


 


4.1.1           Split-Ups. 
If after the date hereof, and subject to the provisions of Section 4.5 below, the number of outstanding Ordinary Shares is
increased by a share dividend payable in Ordinary Shares, or by a split-up of Ordinary Shares or other similar event, then, on
the effective date of such share dividend, split-up or similar event, the number of Ordinary Shares issuable on exercise of each
Warrant shall be increased in proportion to such increase in the outstanding Ordinary Shares and the Exercise Price shall be proportionally
decreased such that the aggregate Exercise Price, after such adjustments, remains the same for each Warrant.


 


4.1.2           Dividends
and Other Distributions. If the Company shall declare or make any dividend or other distribution of its assets (or rights to
acquire its assets) to holders of Ordinary Shares, by way of return of capital or otherwise (including, without limitation, any
distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction), except to the extent an adjustment was already made pursuant
to Section 4.1.1 or 4.2 (a “Distribution”), at any time after the issuance of a Warrant, then, in each such
case, the Company shall reserve and put aside the maximum Distribution amount the Registered Holder would have been entitled to
receive if the Registered Holder had held the number Ordinary Shares acquirable upon complete exercise of such Warrant immediately
before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
holders of Ordinary Shares are to be determined for the participation in such Distribution. Upon exercise of a Warrant, in whole
or in part, the Company shall, contemporaneously with the delivery of the Ordinary Shares, distribute to the Registered Holder
a pro rata portion of such Distribution based on the portion of the Warrant that has been exercised (provided, however,
to the extent that the Registered Holder’s right to participate in any such Distributions would result in the Registered
Holder exceeding the Maximum Percentage, then the Registered Holder shall not be entitled to participate in such Distribution at
such time and to such extent (or the beneficial ownership of any such Ordinary Shares as a result of such Distribution to such
extent) and such Distribution to such extent shall be held in abeyance for the benefit of the Registered Holder until such time,
if ever, as its right thereto would not result in the Registered Holder exceeding the Maximum Percentage, at which time or times
the Registered Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or
on any subsequent Distribution to be held similarly in abeyance) to the same extent as if there had been no such limitation).


 




    5 


     


    




 


4.2          Aggregation
of Shares. If after the date hereof, and subject to the provisions of Section 4.5
hereof, the number of outstanding Ordinary Shares is decreased by a consolidation, combination, reverse share split or reclassification
of Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split,
reclassification or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be decreased in proportion
to such decrease in outstanding Ordinary Shares and the Exercise Price shall be proportionally increased such that the aggregate
Exercise Price, after such adjustments, remains the same for each Warrant.


 


4.3          Purchase
Rights. If at any time the Company grants, issues or sells any options, convertible securities
or rights to purchase shares, warrants, securities or other property pro rata to the record holders of Ordinary Shares (the “Purchase
Rights”), then the Registered Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which the Registered Holder could have acquired if the Registered Holder had held the number of Ordinary
Shares acquirable upon complete exercise of a Warrant immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that
the Registered Holder’s right to participate in any such Purchase Right would result in the Registered Holder exceeding the
Maximum Percentage, then the Registered Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Registered Holder until such time, if ever, as its right thereto would not result in the Registered
Holder exceeding the Maximum Percentage, at which time or times the Registered Holder shall be granted such right (and any Purchase
Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance)
to the same extent as if there had been no such limitation).


 


4.4          Adjustment
Upon Issuance of Ordinary Shares. If and whenever on or after the date of this Agreement and prior
to [          ], 2016 [Insert 18 months following closing]
(the “Applicable Period”), the Company issues, sells or delivers, or in accordance with this Section 4
is deemed to have issued, sold or delivered, any Ordinary Shares, for a consideration per share (the “New
Issuance Price”) less than a price equal to the Exercise Price, in effect immediately prior to such issuance, sale
or delivery or deemed issuance, sale or delivery (such Exercise Price, then in effect is referred to as the
“Applicable Price”) (the foregoing a “Dilutive Issuance”), then immediately after such
Dilutive Issuance, the Exercise Price then in effect shall be reduced one-time only to the product of New Issuance Price
multiplied by 125%. No adjustment pursuant to this Section 4.4 shall be made if such adjustment would result in an increase
of the Exercise Price then in effect. For all purposes of the foregoing (including, without limitation, determining the
adjusted Exercise Price and consideration per share under this Section 4.4), the following shall be applicable:


 




    6 


     


    




 


4.4.1           Issuance
of Options. If the Company grants or sells any options (other than options that qualify as Excluded Securities) during the
Applicable Period and the lowest price per share for which one Ordinary Share is issuable upon the exercise of any such option
or upon conversion, exercise or exchange of any convertible securities issuable upon exercise of any such option is less than the
Applicable Price, then such Ordinary Share shall be deemed to be outstanding and to have been issued and sold or delivered by the
Company at the time of the granting or sale of such option for the New Issuance Price. For purposes of this Section 4.4.1, the
“lowest price per share for which one Ordinary Share is issuable upon the exercise of any such options or upon conversion,
exercise or exchange of any convertible securities issuable upon exercise of any such option” shall be equal to  the lower
of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one Ordinary
Share upon the granting or sale of such option, upon exercise of such option and upon conversion, exercise or exchange of any Convertible
Security issuable upon exercise of such option and (y) the lowest exercise price set forth in such option for which one Ordinary
Shares is issuable upon the exercise of any such options or upon conversion, exercise or exchange of any convertible securities
issuable upon exercise of any such option. Except as contemplated below, no further adjustment of the Exercise Price shall be made
upon the actual issuance of such Ordinary Shares or of such convertible securities upon the exercise of such options or upon the
actual issuance of such Ordinary Shares upon conversion, exercise or exchange of such convertible securities. 


 


4.4.2           Issuance
of Convertible Securities. If the Company issues or sells any convertible securities (other than convertible securities that
qualify as Excluded Securities) during the Applicable Period and the lowest price per share for which one Ordinary Share is issuable
upon the conversion, exercise or exchange thereof is less than the Applicable Price, then such Ordinary Share shall be deemed to
be outstanding and to have been issued and sold or delivered by the Company at the time of the issuance or sale of such convertible
securities for the New Issuance Price. For the purposes of this Section 4.4.2, the “lowest price per share for which one
Ordinary Share is issuable upon the conversion, exercise or exchange thereof” shall be equal to  the lower of (x) the
sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one Ordinary Share upon
the issuance or sale of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security and (y)
the lowest conversion price set forth in such Convertible Security for which one Common Share is issuable upon conversion, exercise
or exchange thereof. Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance
of such Ordinary Shares upon conversion, exercise or exchange of such convertible securities, and if any such issue or sale of
such convertible securities is made upon exercise of any options for which adjustment of Warrants has been or is to be made pursuant
to other provisions of this Section 4.4, except as contemplated below, no further adjustment of the Exercise Price shall be made
by reason of such issue, sale or delivery.


 




    7 


     


    




 


4.4.3           Change
in option Price. If during the Applicable Period the purchase or exercise price provided for in any options, the additional
consideration, if any, payable upon the issue, conversion, exercise or exchange of any convertible securities or the rate at which
any convertible securities are convertible into or exercisable or exchangeable for or Ordinary Shares increases or decreases at
any time, the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would
have been in effect at such time had such options or convertible securities provided for such increased or decreased purchase price,
additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or
sold. For purposes of this Section 4.4.3, if the terms of any option or Convertible Security that was outstanding as of the original
issuance of the Warrants are increased or decreased in the manner described in the immediately preceding sentence, then such option
or Convertible Security and the Ordinary Shares deemed issuable upon exercise, conversion or exchange thereof shall be deemed to
have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section 4.4 shall be made if such
adjustment would result in an increase of the Exercise Price then in effect.


 


4.4.4           Calculation
of Consideration Received. If during the Applicable Period any option and/or Convertible Security is issued in connection with
the issuance or sale or deemed issuance or sale of any other securities of the Company (as determined by the Holder, the “Primary
Security”, and such option and/or Convertible Security, the “Secondary Securities”), together comprising
one integrated transaction, (other than options or Convertible Security that qualify as Excluded Securities) the consideration
per Ordinary Share with respect to such Primary Security shall be deemed to be equal to the difference of (x) the lowest price
per share for which one Ordinary Share was issued in such integrated transaction (or was deemed to be issued pursuant to Section
4.4.1 or 4.4.2 above, as applicable) solely with respect to such Primary Security, minus (y) with respect to such Secondary Securities,
the sum of (I) the Black Scholes Consideration Value of each such option, if any, or (II) the fair market value (as determined
by the Holder) of such Convertible Security, if any, in each case, as determined on a per share basis in accordance with this Section
4.4.4. If any Ordinary Shares, options or convertible securities are issued or sold or deemed to have been issued or sold for cash,
the consideration received therefor (for the purpose of determining the consideration paid for such Ordinary Shares, option or
Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be deemed to be
the net amount of consideration received by the Company therefor. If any Ordinary Shares, options or convertible securities are
issued or sold for a consideration other than cash (for the purpose of determining the consideration paid for such Ordinary Shares,
option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value), the amount
of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists
of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the
arithmetic average of the VWAPs of such security for each of the five (5) trading days immediately preceding the date of receipt.
If any Ordinary Shares, options or convertible securities are issued to the owners of the non-surviving entity in connection with
any merger in which the Company is the surviving entity (for the purpose of determining the consideration paid for such Ordinary
Shares, option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value), the
amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving
entity as is attributable to such, Ordinary Shares, options or convertible securities, as the case may be. The fair value of any
consideration other than cash or publicly traded securities (for the purpose of determining the consideration paid for such Ordinary
Shares, option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will
be determined jointly by the Company and the Holder. If such parties are unable to reach agreement within ten (10) days after the
occurrence of an event requiring valuation (the “Valuation Event”), the fair value of such consideration will
be determined within five (5) trading days after the tenth (10th) day following such Valuation Event by an independent,
reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding
upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. 


 




    8 


     


    




 


4.4.5           For
purposes of this Section 4.4, “Excluded Securities” means (1) Ordinary Shares or options or other rights
to purchase Ordinary Shares or other awards issued or issuable pursuant to the Company’s employee benefit plans,
qualified share option plans or other employee compensation plans as such plans are in existence on the date hereof,
provided; (2) Ordinary Shares issued or issuable upon the conversion, exercise or exchange of convertible securities (other
than options or other rights to purchase Ordinary Shares that are covered by clause (1) above) issued prior to the date
hereof; and (3) Ordinary Shares issuable upon exercise of the Warrants or the certain warrants issued to the underwriters on
March __, 2016 pursuant to the Company’s registered offering which closed on such date; provided, that, notwithstanding the foregoing, such
purchaser or acquirer of the securities in such issuance shall not include any person regularly engaged in the business of
buying or selling securities.


 


For purposes of this
Section 4.4 “VWAP” means, for any date, the price determined by the first of the following clauses that applies:
(a) if the Ordinary Shares are then listed or quoted on the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market or the New York Stock Exchange (each a “Trading Market”), the daily volume weighted
average price of the Ordinary Shares for such date (or the nearest preceding date) on the Trading Market on which the Ordinary
Shares are then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if the Ordinary Shares are not then listed on a Trading Market and if prices for the Ordinary Shares
are then reported in the OTCQB maintained by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per Ordinary Share so reported, or (c) in all other cases, the fair market value
of an Ordinary Share as determined by an independent appraiser selected in good faith by the holders of a majority in interest
of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.


 




    9 


     


    




 


4.5           Fundamental
Transactions. If, at any time while the Warrants are outstanding, (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another person
in which the Company is not the surviving entity or the shareholders of
the Company immediately prior to such merger or consolidation do not own, directly or indirectly, a majority of the outstanding
voting securities of the surviving entity, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment,
transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed
pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary
Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of Ordinary Shares covered by Section 4.1
above), or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding Ordinary Shares
(not including any Ordinary Shares held by the other person or other persons making or party to, or associated or affiliated with
the other persons making or party to, such stock or share purchase agreement or other business combination) (each, a “Fundamental
Transaction”), then, upon any subsequent exercise of a Warrant, the Registered Holder of such Warrant shall be entitled
to receive, for each Ordinary Share that would have been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction (without regard to any limitation in Section 3.4 on the exercise of the Warrants), the number of Ordinary
Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) which, in all cases, was received as a result of such Fundamental Transaction
by a holder of the number of Ordinary Shares for which a Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 3.4 on the exercise of the Warrants). If holders of Ordinary Shares are given any
choice as to the securities, cash or property to be received in a Fundamental Transaction, then each Registered Holder shall be
given the same choice as to the Alternate Consideration. Notwithstanding anything to the contrary, (a) if the holders of Ordinary
Shares received, as a result of such Fundamental Transaction, a consideration or Alternate Consideration (whether from the Company
or from any other person, and whether such consideration or Alternate Consideration is comprised of cash, securities or other property)
(such consideration attributed to one Ordinary Share: the "Fundamental Transaction Consideration Per Ordinary Share")
with respect to some but not all of their Ordinary Shares (including in the event that they have tendered only some of the Ordinary
Shares which such shareholders have initially requested to tender) then, upon any subsequent exercise of a Warrant, the Registered
Holder of such Warrant shall be entitled to receive such consideration on a pro-rata basis, based on the number of Ordinary Shares
underlying its Warrant; and (b) in the event that the Fundamental Transaction Consideration Per Ordinary Share paid as a result
of such Fundamental Transaction is paid by the Successor Entity (as defined below) or by any other person other than the Company,
then such Successor Entity or the other person shall assume and be responsible to pay the Fundamental Transaction Consideration
Per Ordinary Share upon any subsequent exercise of a Warrant.  The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all obligations
of the Company under each Warrant in accordance with the provisions of this Section 4.5 pursuant to agreements in form and substance
reasonably satisfactory to the Registered Holders and approved by the Registered Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of each Registered Holder, deliver to such Registered Holder in exchange for such
Registered Holder’s Warrant a written instrument substantially similar in form and substance to such Registered Holder’s
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the Ordinary Shares acquirable and receivable upon exercise of such Warrant (without regard to the limitations on
exercise set forth in Section 3.4) prior to such Fundamental Transaction, and with an exercise price which applies the Exercise
Price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of such Warrant immediately prior to the consummation of such Fundamental
Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Agreement and each Warrant referring
to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company
and shall assume all of the obligations of the Company under this Agreement and each Warrant with the same effect as if such Successor
Entity had been named as the Company herein.


 




    10 


     


    




 


4.6           Calculations.
All calculations under this Section 4 shall be made to the nearest cent or the nearest whole
share, as the case may be. For purposes of this Section 4, any calculation of the number of Ordinary Shares deemed to be issued
and outstanding as of a given date shall not include treasury shares, if any. In any case in which this Section 4 shall require
that an adjustment in the Exercise Price be made effective as of a record date for a specified event, if the Registered Holder
exercises a Warrant after such record date, the Company may elect to defer, until the occurrence of such event, the issuance of
the Ordinary Shares and other share capital of the Company in excess of the Ordinary Shares and other share capital of the Company,
if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; provided, however,
that in such case the Company or the Warrant Agent shall deliver to the Registered Holder a due bill or other appropriate instrument
evidencing the Registered Holder’s right to receive such additional shares and/or other capital securities upon the occurrence
of the event requiring such adjustment.


 




    11 


     


    




 


4.7           Notices
of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant,
the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from
such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a
Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon
the occurrence of any such adjustment the Company shall give written notice to each Registered Holder, at the last address set
forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice,
or any defect therein, shall not affect the legality or validity of such event. 


 


4.8           No
Fractional Shares. Notwithstanding any provision contained in this Warrant Agreement to the contrary, the Company shall not
issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder
of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company
shall, upon such exercise, round up to the nearest whole number the number of the Ordinary Shares to be issued to the Warrant holder.


 


4.9           Form of Warrant. The form of Warrant need not be changed because of any
adjustment pursuant to this Section 4, and Warrants issued after such adjustment may state the same Exercise Price and the same
number of shares as is stated in the Warrants initially issued pursuant to this Agreement. However, the Company may, at any time,
in its sole discretion, make any change in the form of Warrant that the Company may deem appropriate and that does not affect the
substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant
or otherwise, may be in the form as so changed.


 


4.10         Other
Events. In case any event shall occur affecting the Company as to which none of the provisions
of preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms
of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of
this Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking
or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the
rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine
that an adjustment is necessary, the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that
is consistent with any adjustment recommended in such opinion.


 


5.        
  Transfer and Exchange of Warrants.


 


5.1           Registration
of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant into the Warrant
Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by
appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants
shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the
Warrant Agent to the Company from time to time upon the Company’s request.


 




    12 


     


    

 


 


5.2           Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or
transfer, and, thereupon, the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that, in the event
a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and shall issue
new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such
transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.


 


5.3           Fractional
Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the
issuance of a warrant certificate for a fraction of a warrant.


 


5.4           Warrant
Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever
required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.


 


6.      
    Other Provisions Relating to Rights of Registered Holders of
Warrants.


 


6.1           No
Rights as Shareholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the
Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors
of the Company or any other matter.


 


6.2           Lost,
Stolen Mutilated or Destroyed Warrants. If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant
Agent may, on such terms as to indemnity or otherwise as they may in their discretion impose (which terms shall, in the case of
a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so
lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company,
whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.


 


6.3           Reservation
of Ordinary Shares. The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary
Shares that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.


 




    13 


     


    

 


 


6.4          Registration
of the Ordinary Shares. The Company registered the Warrants and the Ordinary Shares underlying
the Warrants in the Registration Statement. The Company will use its reasonable efforts to maintain the effectiveness of such Registration
Statement and the current status of the Prospectus or to file and maintain the effectiveness of another registration statement
and another current prospectus covering the Ordinary Shares issuable upon exercise of the Warrants at any time that the Warrants
are exercisable.  In addition, the Company agrees to use its reasonable best efforts to register such Ordinary Shares
under the blue sky laws of the states of residence of the exercising Warrant holders to the extent an exemption from such registration
is not available. 


 


7.     
     Concerning the Warrant Agent and Other Matters. 


 


7.1          Payment
of Taxes. The Company shall not be required to pay any stamp or other tax or charge required to be paid in connection with
the exercise of Warrants; and the Company shall not be required to issue or deliver any Ordinary Shares until such tax or other
charge shall have been paid or it has been established to the Company’s and the Warrant Agent’s satisfaction that no
such tax or other charge is due.


 


7.2          Resignation,
Consolidation, or Merger of Warrant Agent.


 


7.2.1           Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the
office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint, in writing,
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of
thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder
of the Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of
any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor
Warrant Agent. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be an entity organized and
existing under the laws of the State of New York, in good standing and have its principal office in the Borough of Manhattan, City
and State of New York, and be authorized under such laws to exercise corporate trust powers and subject to supervision or examination
by federal or state authorities. After appointment, any successor Warrant Agent shall be vested with all the authority, powers,
rights, immunities, duties and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant
Agent hereunder, without any further act or deed; but, if for any reason it becomes necessary or appropriate, the predecessor Warrant
Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all
the authority, powers, and rights of such predecessor Warrant Agent hereunder; and, upon request of any successor Warrant Agent,
the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting
in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties and obligations.


 




    14 


     


    




 


7.2.2           Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Ordinary Shares not later than the effective date of any such appointment.



 


7.2.3           Merger
or Consolidation of Warrant Agent. Any entity into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor
Warrant Agent under this Warrant Agreement without any further act on the part of the Company or the Warrant Agent.


 


7.3          Fees
and Expenses of Warrant Agent.


 


7.3.1           Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as Warrant Agent hereunder as set forth
on Exhibit C hereto and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably
incur in the execution of its duties hereunder.


 


7.3.2           Further
Assurances. The Company agrees to perform, execute, acknowledge and deliver, or cause to be performed, executed, acknowledged
and delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for
the carrying out or performing of the provisions of this Warrant Agreement.


 


7.4          Liability
of Warrant Agent.


 


7.4.1           Reliance
on Company Statement. Whenever, in the performance of its duties under this Warrant Agreement, the Warrant Agent shall deem
it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action
hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be
conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer or Chairman of
the Board of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken
or suffered in good faith by it pursuant to the provisions of this Warrant Agreement.


 


7.4.2           Indemnity.
The Warrant Agent shall be liable hereunder only for its own negligence, willful misconduct or bad faith. The Company agrees to
indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel
fees, for anything done or omitted by the Warrant Agent in the execution of this Warrant Agreement, except as a result of the Warrant
Agent’s negligence, willful misconduct or bad faith.


 




    15 


     


    




 


7.4.3           Exclusions. The Warrant Agent shall have no responsibility with respect
to the validity of this Warrant Agreement or with respect to the validity or execution of any Warrant (except its countersignature
thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Warrant Agreement
or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible
for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such
adjustment; nor shall it, by any act hereunder, be deemed to make any representation or warranty as to the authorization or reservation
of any Ordinary Shares to be issued pursuant to this Warrant Agreement or any Warrant or as to whether any Ordinary Shares will
when issued be valid and fully paid and nonassessable.


 


7.5          Acceptance
of Agency. The Warrant Agent hereby accepts the agency established by this Warrant Agreement and agrees to perform the same
upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares
of the Company’s Ordinary Shares through the exercise of Warrants.


 


8.        
  Miscellaneous Provisions.


 


8.1           Successors.
All the covenants and provisions of this Warrant Agreement by or for the benefit of the Company or the Warrant Agent shall bind
and inure to the benefit of their respective successors and assigns.


 


8.2           Notices.
Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the holder
of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service,
addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:


 


BioLight Life Sciences Ltd.


Kiryat Atidim


Building 3, 5th Floor


Tel Aviv 6158101


Israel


Attn: Suzana Nahum-Zilberberg, Chief Executive Officer


 


Any notice, statement or demand authorized
by this Warrant Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be
delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed
in writing by the Warrant Agent with the Company), as follows:


 


VStock Transfer, LLC

18 Lafayette Place

Woodmere, NY 11598

Attn: Warrant Department


 




    16 


     


    




 


Any notice, sent pursuant to this Warrant
Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight
courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day
after registration or certification thereof


 


8.3           Applicable
Law. The validity, interpretation, and performance of this Warrant Agreement and of the Warrants shall be governed in all respects
by the laws of the State of New York, without giving effect to conflict of laws. The Company hereby agrees that any action, proceeding
or claim against it arising out of or relating in any way to this Warrant Agreement shall be brought and enforced in the courts
of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to
such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by
transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the
address set forth in Section 8.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the
Company in any action, proceeding or claim.


 


8.4           Persons
having Rights Under this Agreement. Nothing in this Agreement shall be construed to confer
upon, or give to, any person or corporation other than the parties hereto and the Registered Holders of the Warrants any right,
remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.
All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive
benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.


 


8.5           Examination of the Warrant Agreement. A copy of this Warrant Agreement shall
be available at all reasonable times at the office of the Warrant Agent for inspection by the Registered Holder of any Warrant.
The Warrant Agent may require any such holder to submit his, her or its Warrant for inspection.


 


8.6           Counterparts-
Facsimile Signatures. This Warrant Agreement may be executed in any number of counterparts, and each of such counterparts shall,
for all purposes, be deemed to be an original, and all such counterparts shall together constitute one and the same instrument.
Facsimile signatures shall constitute original signatures for all purposes of this Warrant Agreement.


 


8.7           Effect
of Headings. The section headings herein are for convenience only and are not part of this Warrant Agreement and shall not
affect the interpretation thereof. 


 




    17 


     


    




 


8.8          Amendments.


 


8.8.1           This
Agreement and any Warrant certificate may be amended by the parties hereto by executing a supplemental warrant agreement (a “Supplemental
Agreement”), without the consent of any of the Registered Holders, for the purpose of (i) curing any ambiguity, or curing,
correcting or supplementing any defective provision contained herein, or making any other provisions with respect to matters or
questions arising under this agreement that is not inconsistent with the provisions of this agreement or the Warrant certificates,
(ii) evidencing the succession of another corporation to the Company and the assumption by any such successor of the covenants
of the Company contained in this agreement and the Warrants, (iii) evidencing and providing for the acceptance of appointment by
a successor Warrant Agent with respect to the Warrants, (iv) adding to the covenants of the Company for the benefit of the Registered
Holders or surrendering any right or power conferred upon the Company under this Agreement, or (viii) amending this agreement and
the Warrants in any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests
of the Registered Holders in any material respect.


 


8.8.2           The
Company and the Warrant Agent may amend this Warrant Agreement and the Warrants by executing a Supplemental Agreement with the
consent of the Registered Holders of not fewer than a majority of the unexercised Warrants affected by such amendment, for the
purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Agreement or of modifying
in any manner the rights of the Registered Holders under this Warrant Agreement; provided, however, that, without the consent of
each of the Registered Holders affected thereby, no such amendment may be made that (i) changes the Warrants so as to reduce the
number of shares purchasable upon exercise of the Warrants or so as to increase the Exercise Price (other than as provided
by Section 4), (ii) shortens the period of time during which the Warrants may be exercised, (iii) otherwise adversely affects the
exercise rights of the Registered Holders in any material respect, or (iv) reduces the number of unexercised Warrants the Registered
Holders of which must consent for amendment of this agreement or the Warrants.


 


8.9          Severability.
This Warrant Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall
not affect the validity or enforceability of this Warrant Agreement or of any other term or provision hereof. Furthermore, in lieu
of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Warrant
Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.


 




    18 


     


    

  


IN WITNESS WHEREOF,
this Warrant Agreement has been duly executed by the parties hereto as of the day and year first above written.


 


	 	BIOLIGHT LIFE SCIENCES LTD.
	 	 	 
	 	By: 	 
	 	 	[Name, Title]
	 	 	 
	 	VSTOCK TRANSFER, LLC
	 	 	 
	 	By:	 
	 	 	[Name, Title]


 




    19 


     


    




 


EXHIBIT A


 


Form of Warrant


 


BIOLIGHT LIFE SCIENCES LTD.

WARRANT CERTIFICATE

NOT EXERCISABLE AFTER __________, _______


 


This certifies that the person whose name
and address appears below, or registered assigns, is the registered owner of the number of Warrants set forth below. Each Warrant
entitles its registered holder to purchase BioLight Life Sciences Ltd., a company incorporated under the laws of the State of Israel
(the “Company”) at any time prior to 5:00 P.M. (New York City time) on ______, _____, at the designated office
of Vstock Transfer LLC, as warrant agent (the “Warrant Agent”) set forth below, one ordinary share, NIS 2.5
per share par value, of the Company (each, a “Share” and collectively, the “Shares”), at
price of US$____ per Share, subject to possible adjustments as provided in the Warrant Agreement (as defined below).


 


This Warrant Certificate, with or without
other Warrant Certificates, upon surrender at the designated office of the Rights Agent, may be exchanged for another Warrant Certificate
or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or Warrant Certificates surrendered.


 


The terms and conditions of the Warrants
and the rights and obligations of the holder of this Warrant Certificate are set forth in a Warrant Agreement dated as of ______,
2016 (the “Warrant Agreement”), between the Company and the Warrant Agent. A copy of the Warrant Agreement is
available for inspection during business hours at the office of the Warrant Agent.


 


This Warrant Certificate shall not be valid
or obligatory for any purpose until it shall have been countersigned by an authorized signatory of the Warrant Agent.


 


WITNESS the facsimile signature of proper
officers of the Company.


 


	 	BIOLIGHT LIFE SCIENCES LTD.
	 	 	 
	 	By: 	 
	 	Name: 
	 	Title:
	 	 	 
	 	By:	 
	 	Name:
	 	Title:


 


Dated:


Countersigned:


 




    20 


     


    




 


VSTOCK TRANSFER, LLC


as Warrant Agent


 


	By: 	 
	Name: 
	Title:


 


	PLEASE DETACH HERE
	 





 


 


Certificate No.:_________ Number of Warrants:__________


 


WARRANT CUSIP NO.: ________


 


BIOLIGHT LIFE SCIENCES LTD.


 


	[Name & Address of Holder]	 	VSTOCK TRANSFER, LTD., Warrant Agent
	 	 	
         

        By mail:

         

        By hand or overnight courier:



 




    21 


     


    




 


EXHIBIT A


 


Form of Election Notice


 


(To Be Executed Upon Exercise Of Warrants)


 


The undersigned hereby
irrevocably elects to exercise the right, represented by Warrants evidenced by this Warrant Certificate, to receive                 
Shares and herewith tenders payment for such Ordinary Shares to the order of BioLight Life Sciences Ltd., in the amount of US$
             in accordance with the terms hereof.


 


 


The undersigned requests
that a certificate for such Ordinary Shares be registered in the name of                     ,
whose address is                     
and that such certificate be delivered to                     ,
whose address is                                         .
If the number of Warrants being exercised hereby is less than all the Warrants evidenced by this Warrant Certificate, the undersigned
requests that a new Warrant Certificate representing the remaining unexercised Warrants be registered in the name of                                         ,
whose address is                                         ,
and that such Warrant Certificate be delivered to                whose
address is                                         .


 


	 	 	Signature
	 	 
	Date:	 	 
	 	 	 
	 	 	Signature Guaranteed


 


Signatures must be guaranteed by an “eligible
guarantor institution” meeting the requirements of the Warrant Agent, which requirements include membership or participation
in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program”
as may be determined by the Warrant Agent in addition to, or in substitution for, STAMP, all in accordance with the Securities
Exchange Act of 1934, as amended.


 




    22 


     


    




 


EXHIBIT C


 


Warrant Agent Fees


 


Monthly Maintenance Fee


 


Our monthly maintenance fee is calculated based upon the number
of record shareholders per class or series of Warrants:


 


	 	o	Monthly Maintenance of 1-99 Registered Holder	$99 per month
	 	o	Monthly Maintenance of 100-200 Registered Holder	$150 per month
	 	o	Monthly Maintenance of 200-300 Registered Holder	$299 per month
	 	o	Monthly Maintenance of 300-500 Registered Holder	$399 per month
	 	o	Monthly Maintenance of 500+ Registered Holder	$749 per month


 


Service Fees


 


The following are a sample of services provided on a per transaction
fee basis as set forth below:


 


	 	o	Per Warrant Exercise	$45.00
	 	o	Issuance Per Warrant	$35.00 
	 	o	Replacement of Lost or Stolen Warrant	$50.00 (paid by Registered Holder)
	 	o	Lost Registered Holder search (if needed)	$5.00 per Registered Holder per search
	 	o	Escheatment (if needed)	$50.00 per Registered Holder


 


Other Costs and Excluded Services


 


The company will be billed separately at
cost for certain out-of-pocket expenses such as postage and courier fees.


 




    23